PREVALENCE OF RIFAMPICIN RESISTANCE AND PROBES IDENTIFICATION OF 81BP RRDR RPO-B GENE IN PULMONARY TUBERCULOSIS PATIENTS OF DISTRICT BANNU, PAKISTAN

Atif Ahmad Khan; Hafiz Ullah Khan; Zarak Khan; Ilyas Khan; Adil Rahim; Asrar Ur Rahman; Qazi Nida Ur-Rehman; Muhammad Roman; Muhammad Sajjad

doi:10.46903/gjms/20.02.1122

PREVALENCE OF RIFAMPICIN RESISTANCE AND PROBES IDENTIFICATION OF 81BP RRDR RPO-B GENE IN PULMONARY TUBERCULOSIS PATIENTS OF DISTRICT BANNU, PAKISTAN

Atif Ahmad Khan, Hafiz Ullah Khan, Zarak Khan, Ilyas Khan, Adil Rahim, Asrar Ur Rahman, Qazi Nida Ur-Rehman, Muhammad Roman, Muhammad Sajjad

Abstract

Background: Tuberculosis is a major public health problem in developing countries due to the emergence of drug resistance against conventional anti-tuberculosis drugs. Rifampicin is considered to be one of the most potent first-line anti-TB drugs but in most cases, it has lost its efficiency due to bacterial resistance. The objective of this study was to detect the prevalence of rifampicin-resistance and probe mutation in 81bp RRDR of the rpo-B gene in Pulmonary TB patients of District Bannu, Pakistan.

Materials and methods: This cross-sectional study was conducted in the Department of Pathology, Bannu Medical College, Bannu from March 2021 to June 2021. The samples were collected for the period from January 2014 to December 2018 and the laboratory tests were performed at the District TB facility DHQ hospital Bannu, Pakistan. A total of 1965 sputum samples were processed by Xpert MTB/RIF assay using the standard N-Acetyl-L-cysteine–NaOH technique.

Results: Among total 1965 processed cases 1382 were MTB positive and the prevalence of rifampicin-resistant detected (RRD) cases among 1382(70.33%) MTB detected pulmonary isolates was 75(5.6%). The mutation detected in 81bp rpo-β Gene was highest in probe E; 42(56%) followed by B; 16(21%), D 09(12%), A 04(5.3%), C 2(2.66%) and B&D/E&D; 01(1.33%).

Conclusion: From the current study, it has been concluded that the prevalence of RRD in Bannu, Pakistan was 5.6% and the most common probe having the highest mutation rate was probe E; 56% followed by B; 21%, D; 12%, A; 5.3%, C; 2.66% and B&D/C&D; 1.33%.

Keywords

Mycobacterium Tuberculosis, Rifampicin, RNA, Gene, Pulmonary Tuberculosis

Full Text:

PDF

References

Bruchfeld J, Correia-Neves M, Källenius G. Tuberculosis and HIV coinfection. Cold Spring Harb Perspect Med 2015 Jul 1; 5(7): a017871.

Grobusch MP, Kapata N. Global burden of tuberculosis: where we are and what to do. Lancet Infect Dis 2018 Dec 1; 18(12):1291-3.

Chakaya J, Khan M, Ntoumi F, Aklillu E, Fatima R, Mwaba P, et al. Global Tuberculosis Report 2020–Reflections on the Global TB burden, treatment and prevention efforts. Int J Infect Dis 2021 Dec 1; 113: S7-12.

Ormerod LP. Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment. Br Med Bull 2005 Jan 1;73(1):17-24.

Taniguchi H, Aramaki H, Nikaido Y, Mizuguchi Y, Nakamura M, Koga T, et al. Rifampicin resistance and mutation of the rpoB gene in Mycobacterium tuberculosis. FEMS Microbiol Lett 1996 Oct 1; 144(1):103-8.

Harding E. WHO global progress report on tuberculosis elimination. Lancet Respir Med 2020 Jan 1; 8(1):19.

Munir MK, Rehman S, Iqbal R. Meeting the challenge, making a difference: Multidrug resistance tuberculosis in Pakistan. Pak J Med Res 2018; 57(1):1-2.

Migliori GB, Tiberi S, Zumla A, Petersen E, Chakaya JM, Wejse C, et al. MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. Int J Infect Dis 2020 Mar 1; 92: S15-25.

Fatima R, Harris RJ, Enarson DA, Hinderaker SG, Qadeer E, Ali K, et al. Estimating tuberculosis burden and case detection in Pakistan. Int J Tuberc Lung Dis 2014 Jan 1; 18(1):55-60.

Oladele RO, Irurhe NK, Foden P, Akanmu AS, Gbaja-Biamila T, Nwosu A, et al. Chronic pulmonary aspergillosis as a cause of smear-negative TB and/or TB treatment failure in Nigerians. Int J Tuberc Lung Dis 2017 Sep 1; 21(9):1056-61.

Goldstein BP. Resistance to rifampicin: a review. J Antibiot 2014 Sep; 67(9):625-30.

Adékambi T, Drancourt M, Raoult D. The rpoB gene as a tool for clinical microbiologists. Trends Microbiol 2009 Jan 1; 17(1):37-45.

Singhal R, Myneedu VP. Microscopy as a diagnostic tool in pulmonary tuberculosis. Int J Mycobacteriol 2015 Mar 1;4(1):1-6.

Robledo JA, Mejia GI, Morcillo N, Chacón L, Camacho M, Luna J, et al. Evaluation of a rapid culture method for tuberculosis diagnosis: a Latin American multi-center study. Int J Tuberc Lung Dis 2006 Jun 1;10(6):613-9.

Steingart KR, Sohn H, Schiller I, Kloda LA, Boehme CC, Pai M, et al. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 2013(1).

Opota O, Senn L, Prod'hom G, Mazza-Stalder J, Tissot F, Greub G, et al. Added value of molecular assay Xpert MTB/RIF compared to sputum smear microscopy to assess the risk of tuberculosis transmission in a low-prevalence country. Clin Microbiol Infect 2016 Jul 1;22(7):613-9.

World Health Organization. Global status report on alcohol and health 2018. WHO; 2019 Feb 14.

Kent PT. Public health mycobacteriology: a guide for the level III laboratory. US Department of Health and Human Services, Public Health Service, Centers for Disease Control; 1985.

Zaw MT, Emran NA, Lin Z. Mutations inside rifampicin-resistance determining region of rpoB gene associated with rifampicin-resistance in Mycobacterium tuberculosis. J Infect Public Health 2018 Sep 1;11(5):605-10.

Qazi O, Rahman H, Tahir Z, Qasim M, Khan S, Anjum AA, et al. Mutation pattern in rifampicin resistance determining region of rpoB gene in multidrug-resistant Mycobacterium tuberculosis isolates from Pakistan. Int J Mycobacteriol 2014 Sep 1; 3(3):173-7.

Ullah I, Shah AA, Basit A, Ali M, Ullah U, Ihtesham M, et al. Rifampicin resistance mutations in the 81 bp RRDR of rpo B gene in Mycobacterium tuberculosis clinical isolates using Xpert MTB/RIF in Khyber Pakhtunkhwa, Pakistan: a retrospective study. BMC Infect Dis 2016 Dec;16(1):1-6.

Bakuła Z, Javed H, Pleń M, Jamil N, Tahir Z, Jagielski T. Genetic diversity of multidrug-resistant Mycobacterium tuberculosis isolates in Punjab, Pakistan. Infect Genet Evol 2019 Aug 1; 72:16-24.

Gautam PB, Mishra A, Kumar S. Prevalence of rifampicin resistant mycobacterium tuberculosis and associated factors among presumptive tuberculosis patients in eastern Uttar Pradesh: a cross sectional study. Int J Community Med Public Health 2018 Jun; 5(6):2271-6.

Arega B, Menbere F, Getachew Y. Prevalence of rifampicin resistant Mycobacterium tuberculosis among presumptive tuberculosis patients in selected governmental hospitals in Addis Ababa, Ethiopia. BMC Infect Dis 2019 Dec; 19(1):1-5.

Ikuabe PO, Ebuenyi ID. Prevalence of rifampicin resistance by automated Genexpert rifampicin assay in patients with pulmonary tuberculosis in Yenagoa, Nigeria. Pan Afr Med J 2018; 29.

Khan SN, Niemann S, Gulfraz M, Qayyum M, Siddiqi S, Mirza ZS, et al. Molecular characterization of multidrug-resistant isolates of Mycobacterium tuberculosis from patients in Punjab, Pakistan. Pak J Zool 2013 Feb 1;45(1).

Yue J, Shi W, Xie J, Li Y, Zeng E, Wang H. Mutations in the rpoB gene of multidrug-resistant Mycobacterium tuberculosis isolates from China. J Clin Microbiol 2003 May; 41(5):2209-12.

Mboowa G, Namaganda C, Ssengooba W. Rifampicin resistance mutations in the 81 bp RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert® MTB/RIF in Kampala, Uganda: a retrospective study. BMC Inf Dis 2014 Sep 4; 14:481. DOI: 10.1186/1471-2334-14-481.

DOI: https://doi.org/10.46903/gjms/20.02.1122